On the stock market since 2019, it operates in the world of health and science. It has 418 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 128% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 89% a year on average.
The company sells $521.3M a year; the problem isn’t sales — it’s costs running above that number.
There is $383.3M in the vault; even if every debt were paid off, $63.9M would remain.
A loss of $23.4M against $521.3M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 27/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 42/100.
On our five-subject report card, MIRM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MIRM has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (42/100) says the stock isn’t cheap.